Qiagen N.V.
NYSEQGEN reports today with one of the most striking options setups in its recent history — and the signal is unusually bullish. The put/call ratio has collapsed to just 0.03, nearly 1.6 standard deviations below its 20-day average of 0.36. That reading is close to the lowest of the past year, and marks a dramatic reversal from the 0.66 PCR that prevailed through most of July. In…
QGEN cost to borrow surges 221% over one week to 2.02%, signaling tightening share availability for short sellers.
QGEN reports today with one of the most striking options setups in its recent history — and the signal is unusually bullish. The put/call ratio has collapsed to just 0.03, nearly 1.6 standard deviations below its…
Qiagen heads into its June 24 earnings release with a fresh analyst upgrade from a bellwether firm landing the day before the print — making the debate between bulls and bears unusually live. Morgan Stanley moved to…
Snapshot as of 6 Aug 2026
QGEN heads into the week of May 20 caught between two competing storylines: a flurry of AI-led product launches and a wave of securities fraud investigations that landed alongside a punishing month-long selloff. The…
QIAGEN entered its Q1 2026 earnings week already nursing a 17% one-month decline. The report did nothing to arrest the slide — and the Street's response was swift and unanimous. Q1 sales came in at $492m, missing the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for QGEN — free to start on ORTEX.
Sign up for free →Open QGEN on ORTEX